Search results
On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23
FierceBiotech· 2 hours agoFive months ago, Merck revealed data that indicate its next-generation pneumococcal vaccine offers more protection for older adults than Pfizer’s market dominator Prevnar ...
FDA Says Vaccination Is the Best Protection Against Measles
Sierra Sun Times· 2 hours agoMeasles is one of the most contagious respiratory diseases in the world that has the potential to be life-threatening. Vaccines approved by the U.S. Food and Drug Administration ...
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer
Nature· 3 days agoDiscover the world’s best science and medicine | Nature.com
Should You Buy Moderna Before May 12?
Motley Fool via Yahoo Finance· 3 days agoThe biotech company aims to bring as many as 15 new products to market over the next five years and has the late-stage pipeline to support...is set to...
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for...
Morningstar· 7 days agoImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Designated ...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 5 days agoThe RS Rating is a 1-99 measure of a stock's 12-month performance. This means Moderna stock outranks...
Merck Stock Jumps After Dow Jones Stalwart Rides Its Cancer 'Star' To Another Quarterly Beat
Investor's Business Daily· 4 days agoMerck noted that the devaluation of the Argentine peso had a 2% impact on sales. Minus that factor,...
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 5 days agoThe RS Rating measures a stock's 12-month running performance against all other stocks. That RS...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 4 days agoQuarter in Detail The Pharmaceutical segment generated revenues of $14.0 billion, up 9% year over...
Why Is ImmunityBio Stock Trading Higher On Tuesday? - ImmunityBio (NASDAQ:IBRX)
Benzinga· 6 days agoThe drug is combined with the BCG vaccine, mainly used against tuberculosis and as a common treatment for some forms of bladder cancer. Last year in May, the FDA issued a ...